# TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

> **NCT02586675** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 7 (actual)

## Conditions studied

- Breast Cancer
- Breast Cancer - Female
- Breast Cancer - Male

## Interventions

- **DRUG:** Tamoxifen
- **DRUG:** Ribociclib
- **DRUG:** Goserelin

## Key facts

- **NCT ID:** NCT02586675
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-23
- **Primary completion:** 2017-05-08
- **Final completion:** 2021-10-27
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2022-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02586675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02586675, "TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02586675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*